|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Stat Facts: Ovarian Cancer. 2019.
PubMed/NCBI
|
|
3
|
Ozols RF: Systemic therapy for ovarian
cancer: Current status and new treatments. Semin Oncol. 33 (Suppl
6):S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karnezis AN, Cho KR, Gilks CB, Pearce CL
and Huntsman DG: The disparate origins of ovarian cancers:
Pathogenesis and prevention strategies. Nat Rev Cancer. 17:65–74.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kurman RJ and Shih IeM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seidman JD, Horkayne-Szakaly I, Haiba M,
Boice CR, Kurman RJ and Ronnett BM: The histologic type and stage
distribution of ovarian carcinomas of surface epithelial origin.
Int J Gynecol Pathol. 23:41–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peres LC, Cushing-Haugen KL, Köbel M,
Harris HR, Berchuck A, Rossing MA and Doherty JA: Invasive
epithelial ovarian cancer survival by histotype and disease stage.
J Natl Cancer Inst. 111:60–68. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pilié PG, Tang C, Mills GB and Yap TA:
State-of-the-art strategies for targeting the DNA damage response
in cancer. Nat Rev Clin Oncol. 16:81–104. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
AlHilli MM, Becker MA, Weroha SJ, Flatten
KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou
X, et al: In vivo anti-tumor activity of the PARP inhibitor
niraparib in homologous recombination deficient and proficient
ovarian carcinoma. Gynecol Oncol. 143:379–388. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McGuire WP III and Markman M: Primary
ovarian cancer chemotherapy: Current standards of care. Br J
Cancer. 89 (Suppl 3):S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pokhriyal R, Hariprasad R, Kumar L and
Hariprasad G: Chemotherapy resistance in advanced ovarian cancer
patients. Biomark Cancer. 11:1179299X198608152019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim G, Ison G, McKee AE, Zhang H, Tang S,
Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA approval
summary: Olaparib monotherapy in patients with deleterious germline
BRCA-mutated advanced ovarian cancer treated with three or more
lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briggs MW and Sacks DB: IQGAP proteins are
integral components of cytoskeletal regulation. EMBO Rep.
4:571–574. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weissbach L, Settleman J, Kalady MF,
Snijders AJ, Murthy AE, Yan YX and Bernards A: Identification of a
human rasGAP-related protein containing calmodulin-binding motifs.
J Biol Chem. 269:20517–20521. 1994.PubMed/NCBI
|
|
18
|
Hedman AC, Smith JM and Sacks DB: The
biology of IQGAP proteins: Beyond the cytoskeleton. EMBO Rep.
16:427–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swart-Mataraza JM, Li Z and Sacks DB:
IQGAP1 is a component of Cdc42 signaling to the cytoskeleton. J
Biol Chem. 277:24753–24763. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Y, Olufemi L, Wang MT and Nie D: Role
of Rho GTPases in breast cancer. Front Biosci. 13:759–776. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Erickson JW and Cerione RA: Multiple roles
for Cdc42 in cell regulation. Curr Opin Cell Biol. 13:153–157.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arias-Romero LE and Chernoff J: Targeting
Cdc42 in cancer. Expert Opin Ther Targets. 17:1263–1273. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnson M, Sharma M and Henderson BR:
IQGAP1 regulation and roles in cancer. Cell Signal. 21:1471–1478.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mataraza JM, Briggs MW, Li Z, Entwistle A,
Ridley AJ and Sacks DB: IQGAP1 promotes cell motility and invasion.
J Biol Chem. 278:41237–41245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmidt VA, Chiariello CS, Capilla E,
Miller F and Bahou WF: Development of hepatocellular carcinoma in
Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol.
28:1489–1502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nojima H, Adachi M, Matsui T, Okawa K and
Tsukita S and Tsukita S: IQGAP3 regulates cell proliferation
through the Ras/ERK signalling cascade. Nat Cell Biol. 10:971–978.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang S, Watanabe T, Noritake J, Fukata M,
Yoshimura T, Itoh N, Harada T, Nakagawa M, Matsuura Y, Arimura N
and Kaibuchi K: IQGAP3, a novel effector of Rac1 and Cdc42,
regulates neurite outgrowth. J Cell Sci. 120:567–577. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Y, Zhao W, Xu QW, Wang XS, Zhang Y
and Zhang J: IQGAP3 promotes EGFR-ERK signaling and the growth and
metastasis of lung cancer cells. PLoS One. 9:e975782014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu G, Xu Y, Chen W, Wang J, Zhao C and
Wang M: RNA Interference of IQ motif containing GTPase-activating
protein 3 (IQGAP3) inhibits cell proliferation and invasion in
breast carcinoma cells. Oncol Res. 24:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi Y, Qin N, Zhou Q, Chen Y, Huang S,
Chen B, Shen G and Jia H: Role of IQGAP3 in metastasis and
epithelial-mesenchymal transition in human hepatocellular
carcinoma. J Transl Med. 15:1762017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao H, Wang Q, Gao Z, Xu X, Lu Q and Wu Y:
Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in
the diagnosis and prognostic evaluation of colorectal cancer.
Cancer Cell Int. 19:1632019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu J, Chen Z, Cao H, Yu Z, Feng J, Wang K,
Lu Q and Wu Y: High expression of IQGAP3 indicates poor prognosis
in colorectal cancer patients. Int J Biol Markers. 34:348–355.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yasui W, Sentani K, Sakamoto N, Anami K,
Naito Y and Oue N: Molecular pathology of gastric cancer: Research
and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu W, Xu B, Yao Y, Yu X, Cao H, Zhang J,
Liu J and Sheng H: Overexpression and biological function of IQGAP3
in human pancreatic cancer. Am J Transl Res. 8:5421–5432.
2016.PubMed/NCBI
|
|
36
|
Javadi S, Ganeshan DM, Qayyum A, Iyer RB
and Bhosale P: Ovarian cancer, the revised FIGO staging system, and
the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Birrer MJ, Johnson ME, Hao K, Wong KK,
Park DC, Bell A, Welch WR, Berkowitz RS and Mok SC: Whole genome
oligonucleotide-based array comparative genomic hybridization
analysis identified fibroblast growth factor 1 as a prognostic
marker for advanced-stage serous ovarian adenocarcinomas. J Clin
Oncol. 25:2281–2287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferriss JS, Kim Y, Duska L, Birrer M,
Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene
expression predictors of single drug responses to adjuvant
chemotherapy in ovarian carcinoma: Predicting platinum resistance.
PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarzab M, Student S,
Rzepecka IK, Jarzab B and Kupryjańczyk J: Gene expression analysis
in ovarian cancer-faults and hints from DNA microarray study. Front
Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S,
Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, et al: Integrated
copy number and expression analysis identifies profiles of
Whole-arm chromosomal alterations and subgroups with favorable
outcome in ovarian clear cell carcinomas. PLoS One.
10:e01280662015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pokharel D, Roseblade A, Oenarto V, Lu JF
and Bebawy M: Proteins regulating the intercellular transfer and
function of P-glycoprotein in multidrug-resistant cancer.
Ecancermedicalscience. 11:7682017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Campos SM and Ghosh S: A current review of
targeted therapeutics for ovarian cancer. J Oncol. 149362:2010.
|
|
48
|
Hogberg T: Chemotherapy: Current drugs
still have potential in advanced ovarian cancer. Nat Rev Clin
Oncol. 7:191–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
White CD, Khurana H, Gnatenko DV, Li Z,
Odze RD, Sacks DB and Schmidt VA: IQGAP1 and IQGAP2 are
reciprocally altered in hepatocellular carcinoma. BMC
Gastroenterol. 10:1252010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S,
Liu D, Ye X, Ye M, Yang J, et al: Frequent alterations in
cytoskeleton remodelling genes in primary and metastatic lung
adenocarcinomas. Nat Commun. 6:101312015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guan X: Cancer metastases: Challenges and
opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang RY, Chung VY and Thiery JP:
Targeting pathways contributing to epithelial-mesenchymal
transition (EMT) in epithelial ovarian cancer. Curr Drug Targets.
13:1649–1653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Berx G, Raspe E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
McAuliffe P, Meric-Bernstam F, Mills GB
and Gonzalez-Angulo A: Deciphering the role of PI3K/Akt/mTOR
pathway in breast cancer biology and pathogenesis. Clin Breast
Cancer. 10 (Suppl 3):S59–S65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gasparri ML, Bardhi E, Ruscito I, Papadia
A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD and
Benedetti Panici P: PI3K/AKT/mTOR pathway in ovarian cancer
treatment: Are we on the right track? Geburtshilfe Frauenheilkd.
77:1095–1103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q:
Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol
Cancer. 14:482015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Melendez J, Grogg M and Zheng Y: Signaling
role of Cdc42 in regulating mammalian physiology. J Biol Chem.
286:2375–2381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Morgan CJ, Hedman AC, Li Z and Sacks DB:
Endogenous IQGAP1 and IQGAP3 do not functionally interact with Ras.
Sci Rep. 9:110572019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ramus SJ and Gayther SA: The contribution
of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 3:138–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jiang X, Li X, Li W, Bai H and Zhang Z:
PARP inhibitors in ovarian cancer: Sensitivity prediction and
resistance mechanisms. J Cell Mol Med. 23:2303–2313. 2019.
View Article : Google Scholar : PubMed/NCBI
|
